Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 3/20 | 0.40 |
| ▸ | FASN | P49327 | 6/20 | 0.39 |
| ▸ | EGLN1 | Q9GZT9 | 5/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2366424 | 1.00 | ADRA1A (0.40) | ADRA1AFASNEGLN1PIK3CAALDH1A1 | |
| SCHEMBL2366217 | 0.92 | ADRA1A (0.40) | ADRA1AFASNEGLN1PIK3CAALDH1A1 | |
| SCHEMBL2366224 | 0.92 | ADRA1A (0.40) | ADRA1AFASNEGLN1PIK3CAALDH1A1 | |
| SCHEMBL2366510 | 0.92 | FASN (0.39) | ADRA1AFASNEGLN1ALDH1A1RAB9A | |
| SCHEMBL2366502 | 0.92 | FASN (0.39) | ADRA1AFASNEGLN1ALDH1A1RAB9A | |
| SCHEMBL12240526 | 0.91 | FASN (0.39) | ADRA1AFASNEGLN1ALDH1A1RAB9A | |
| SCHEMBL2366652 | 0.91 | LMNA (0.39) | EGLN1PIK3CAALDH1A1NTSR1MEN1 | |
| SCHEMBL2366647 | 0.91 | LMNA (0.39) | EGLN1PIK3CAALDH1A1NTSR1MEN1 | |
| Hydrochloric Acid SCHEMBL2380663 | 0.91 | FASN (0.38) | FASNEGLN1ALDH1A1RAB9AMEN1 | |
| Hydrochloric Acid SCHEMBL2380655 | 0.91 | FASN (0.38) | FASNEGLN1ALDH1A1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2364975-B1 | NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-06-12 | — | — | EP | disclosed |
| US-8354401-B2 | Oxazolidinone amide aromatic compounds for supressing MMP-9 production | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-01-15 | — | — | US | disclosed |
| US-8354401-B2 | Oxazolidinone amide aromatic compounds for supressing MMP-9 production | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-01-15 | — | — | US | disclosed |
| US-8354401-B2 | Oxazolidinone amide aromatic compounds for supressing MMP-9 production | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-01-15 | — | — | US | disclosed |
| US-20110263571-A1 | NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-10-27 | — | — | US | disclosed |
| US-20110263571-A1 | NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-10-27 | — | — | US | disclosed |
| US-20110263571-A1 | NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-10-27 | — | — | US | disclosed |
| EP-2364975-A1 | NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE | Mitsubishi Tanabe Pharma Corporation (JP) | 2011-09-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263571-A1 | NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE | MMP9, MMP10, MMP2 | ADRA1A 4758/4885FASN 3089/4885EGLN1 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.